ALIVUS vs JBCHEPHARM: Stock Comparison
Alivus Life Sciences Limited vs JB Chemicals & Pharmaceuticals Limited
Live data: 27 July 2026, 10:41 AM IST • Source: NSE and company filings
JB Chemicals & Pharmaceuticals Limited is the larger company by market capitalisation. Alivus Life Sciences Limited shows a lower P/E, faster revenue growth and a higher net margin, while JB Chemicals & Pharmaceuticals Limited shows a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Side-by-side comparison of Alivus Life Sciences Limited and JB Chemicals & Pharmaceuticals Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ALIVUS | JBCHEPHARM |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | ALIVUS | JBCHEPHARM |
|---|---|---|
| Live Price | ₹1,128 | ₹2,408.9 |
| Day Change | 2.43% | -3.87% |
| Volume | 31,486 | 47.79 L |
| 52-Week High | ₹1,193.9 | ₹2,525.5 |
| 52-Week Low | ₹819 | ₹1,638.5 |
| Distance from 52W High | -5.52% | -4.62% |
Valuation
| Metric | ALIVUS | JBCHEPHARM |
|---|---|---|
| Market Cap | ₹13,895 Cr | ₹38,731 Cr |
| P/E Ratio | 23.94x | 54.59x |
| P/B Ratio | 4.06x | 9.31x |
| EPS | ₹45.92 | ₹44.49 |
| Book Value | ₹271.02 | ₹259.05 |
| Dividend Yield | 0.45% | 1.19% |
Growth
| Metric | ALIVUS | JBCHEPHARM |
|---|---|---|
| Revenue Growth (TTM YoY) | 6.1% | -4.8% |
| EPS Growth (TTM YoY) | 14.5% | -31% |
| Qtr Sales Growth | — | -4.77% |
| Qtr Profit Growth | — | -17% |
Profitability & Leverage
| Metric | ALIVUS | JBCHEPHARM |
|---|---|---|
| ROE | — | 18.9% |
| ROCE | — | 25.4% |
| Net Margin | 22.05% | 17.1% |
| Operating Margin | 31.4% | 26.7% |
| Debt to Equity | — | 0x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | ALIVUS | JBCHEPHARM |
|---|---|---|
| Promoter Holding | 74.87% | 48.8%▲ 48.8 pp |
| FII Holding | 5.54%▲ 0.25 pp | 16.33%▲ 1.45 pp |
| DII Holding | 7.18%▼ 0.1 pp | 21.38%▼ 1.98 pp |
| Public Holding | 12.41%▼ 0.15 pp | 13.48%▼ 0.74 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Alivus Life Sciences Limited and JB Chemicals & Pharmaceuticals Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.